M. Campone

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Sylvia Adams, P. Schmid, H. S. Rugo et al. · Annals of Oncology · 2018 · 756 citations · Full text

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours

M. Campone, Vincent Lévy, Emmanuelle Bourbouloux et al. · British Journal of Cancer · 2009 · 97 citations · Full text

LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

G. N. Hortobágyi, Salomon M. Stemmer, H.A. Burris et al. · Annals of Oncology · 2021 · 73 citations

Endocrine Oncology, Breast Oncology, Phase Iii Monaleesa-2 +9

Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial

Bohuslav Melichar, E. Casado, J.A. Bridgewater et al. · British Journal of Cancer · 2011 · 17 citations · Full text

Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE).

Catherine Van Poznak, R.A. Hannon, Glen Clack et al. · Cancer Research · 2009 · 16 citations

Gynecology, 24-Month Results, Pharmacotherapy +22